Bristol Myers Squibb is defending its clinical pipeline after a patient death in an autoimmune trial, reassuring investors over its broader immunology strategy.

A dramatic shift in federal oversight permitting certain unapproved peptides has rattled pharmaceutical giants while igniting a boom for alternative wellness markets.

Federal indictments involving college campuses have accelerated regulatory oversight, threatening the commercial expansion of legitimate ketamine clinics and psychedelic therapeutics.

AstraZeneca is advancing a portfolio of targeted cancer therapies to protect oncology margins and achieve its ambitious 2030 revenue targets.

Shares of Genmab surged following encouraging clinical data from its oncology program, lifting sentiment across the European and U.S. biotechnology sectors.

Bayer has gained regulatory clearance in China for its novel stroke-prevention medication, capturing a global first-in-class approval as it rebuilds its cardiovascular pipeline.

Growing ideological rifts between wellness reformists and traditional deregulation conservatives are forcing healthcare and food industry leaders to recalibrate their regulatory strategies.